Firmonertinib 160mg in EGFR-Mutated NSCLC with Brain Metastases After EGFR-TKI Resistance (iFORCE): Clinical Outcomes and Mechanistic Insights.
BACKGROUND Brain metastases (BM) are frequent in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) and remain challenging after prior EGFR tyrosine kinase inhibitor (TKI) therapy. This exploratory study evaluated high-dose fimmonertinib and explored subtype-specific spatial biology. METHODS iFORCE was a prospec...